AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 87 filers reported holding AVADEL PHARMACEUTICALS PLC in Q2 2022. The put-call ratio across all filers is 0.83 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212,145 | -34.5% | 20,597 | +4.9% | 0.00% | -100.0% |
| Q2 2023 | $323,663 | +105.4% | 19,640 | +14.2% | 0.00% | – |
| Q1 2023 | $157,561 | +23.5% | 17,201 | -3.4% | 0.00% | – |
| Q4 2022 | $127,580 | +57.5% | 17,801 | +10.6% | 0.00% | – |
| Q3 2022 | $81,000 | +1520.0% | 16,101 | +657.3% | 0.00% | – |
| Q2 2022 | $5,000 | -66.7% | 2,126 | 0.0% | 0.00% | – |
| Q1 2022 | $15,000 | -16.7% | 2,126 | -2.9% | 0.00% | – |
| Q4 2021 | $18,000 | -14.3% | 2,189 | +1.1% | 0.00% | – |
| Q3 2021 | $21,000 | -69.6% | 2,166 | -78.8% | 0.00% | – |
| Q2 2021 | $69,000 | -31.7% | 10,213 | -8.9% | 0.00% | – |
| Q1 2021 | $101,000 | +34.7% | 11,213 | 0.0% | 0.00% | – |
| Q4 2020 | $75,000 | -6.2% | 11,213 | -29.7% | 0.00% | – |
| Q3 2020 | $80,000 | +66.7% | 15,951 | +165.8% | 0.00% | – |
| Q2 2020 | $48,000 | +700.0% | 6,000 | +757.1% | 0.00% | – |
| Q1 2020 | $6,000 | – | 700 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |